Claims for Patent: 5,298,422

Summary for Patent: 5,298,422

Title:	Myogenic vector systems
Abstract:	The present invention includes a Myogenic vector system (MVS) for the expression of a nucleic acid sequence in myogenic tissue. The MVS contains a promoter, a cassette with the sequence of interest, a 3\' untranslated region (3\' UTR) and contiguous noncoding region (NCR). Further enhancements can include the addition of a leader sequence, intron sequence, initiation codon and specific This invention was partially supported by a grant from the United States government under HL-38401 awarded by the National Institute of Health. The Government has certain rights in the invention.
Inventor(s):	Schwartz; Robert J. (Houston, TX), DeMayo; Franco J. (Houston, TX), O\'Malley; Bert W. (Houston, TX)
Assignee:	Baylor College of Medicine (Houston, TX)
Application Number:	07/789,919
Patent Claims:	1. A myogenic vector system (MVS) for the expression of a nucleic acid sequence in myogenic tissue, comprising a promoter; a cassette whose 5' end is attached to the 3' end of the promoter, said cassette containing a nucleic acid sequence which is to be expressed; a myogenic specific 3' untranslated region (3'UTR) and a non-coding region (NCR) contiguous to the 3' end of the 3' UTR, said NCR containing a transcriptional termination signal, wherein the 5' end of the 3' UTR is attached to the 3' end of the cassette. 2. The MVS of claim 1, further comprising a 5' MRNA leader sequence inserted between the promoter and cassette, wherein the 5' end of said leader sequence is attached to the promoter and the 3' end is attached to the cassette. 3. A MVS for the expression of a nucleic acid sequence in myogenic tissues comprising a functional unit which expresses the nucleic acid sequence, wherein the functional unit is comprised of elements all sequentially linked together 5' to 3', said elements include a promoter; a 5' MRNA leader sequence; a first intron; an initiation ATG and NcoI cloning site; a cassette, wherein the cassette has an EcoR1 site at its 3' end and contains the nucleic acid sequence to be expressed; a myogenic specific 3' untranslated region (3' UTR); and a non-coding region (NCR) contiguous to the 3' end of the 3'UTR, said NCR containing a transcriptional termination signal. 4. The MVS of claim 1 or 3, wherein the promoter is myogenic specific. 5. The MVS of claim 2 or 3, wherein the leader sequence is myogenic specific. 6. The MVS of claim 1 or 3, wherein the promoter is selected from the group consisting of skeletal alpha actin gene promoter, fast myosin light chain 1 promoter, myosin heavy chain promoter, tropinin T promoter, muscle creatinine kinase promoter/enhancer, acetycholine receptor subunits, cytomegalovirus promoter, RSV promoter and Rous Sarcoma virus LTR. 7. The MVS of claim 1 or 3, wherein the promoter is a skeletal alpha actin gene promoter. 8. A myogenic vector system (MVS) for the expression of a nucleic acid sequence in myogenic tissue, comprising: a 5' oligonucleotide, said oligonucleotide including a promoter; a 3' oligonucleotide containing a myogenic specific 3' untranslated region (3' UTR) and a non-coding region (NCR) contiguous to the 3' end of the 3' UTR, said NCR containing a transcriptional termination signal; and a linker, having a plurality of restriction endonuclease sites, said linker connecting the 5' oligonucleotide to the 3' oligonucleotide and said linker further providing a position for insertion of a cassette containing the nucleic acid to be expressed. 9. The MVS of claim 1, 3 or 8, wherein the 3' UTR and NCR are selected from the group consisting of skeletal alpha actin gene, fast myosin light chain 1 gene, myosin heavy chain gene, tropinin T gene and muscle creatinine kinase gene. 10. The MVS of claim 1, 3 or 8, wherein the 3' UTR and NCR are from a skeletal alpha actin gene. 11. The MVS of claim 1, 3 or 8, further comprising a regulator system for regulating the expression of the nucleic acid sequence. 12. The MVS of claim 10 wherein said regulator system comprising at least one regulatory promoter element which responds to at least one serum response factor and at least one of the serum response factors is a chimera, having its DNA binding domain replaced with a receptor DNA binding sequence. 13. The MVS of claim 12, wherein the receptor binding site of the serum response factor is selected from the family of receptors consisting of vitamin, steroid, thyroid, orphan, hormone, retenoic acid, and thyroxine. 14. The MVS of claim 12, wherein the receptor binding site of the serum response factor is a Vitamin D receptor. 15. The MVS of claim 1, 3 or 8, wherein the expressed nucleic acid sequence codes for a polypeptide. 16. The MVS of claim 1, 3 or 8, wherein the expressed nucleic acid sequence codes for a polypeptide selected from the group consisting of a hormone, growth factor, enzyme, apolipoprotein clotting factor, tumor suppressor, tumor antigen, viral protein, bacterial surface protein, and parasitic cell surface protein. 17. The MVS of claim 1, 3 or 8, wherein the expressed nucleic acid sequence codes for insulin like growth factor I, insulin like growth factor II or insulin growth factor binding protein. 18. The MVS of claim 1, 3 or 8, wherein the expressed nucleic acid sequence codes for growth hormone releasing hormone. 19. The MVS of claim 1, 3 or 8, wherein the expressed nucleic acid sequence codes for apolipoprotein A-I. 20. The MVS of claim 11, wherein the expressed nucleic acid sequence codes for insulin like growth factor I, insulin like growth factor II or insulin growth factor binding protein. 21. The MVS of claim 11, wherein the expressed nucleic acid sequence codes for growth hormone releasing hormone. 22. The MVS of claim 11, wherein the expressed nucleic acid sequence codes for apolipoprotein A-I. 23. A regulatable myogenic vector system (MVS) for the expression of a specific nucleic acid sequence in myogenic tissue comprising: a first functional unit, elements of said first unit comprise a myogenic specific promoter; a nucleic acid sequence coding for a receptor; a myogenic specific 3' untranslated region (3' UTR) and a myogenic specific non-coding region (NCR); wherein the elements of the first unit are linked together sequentially starting from the 5' end with the promoter, followed by the receptor nucleic acid sequence, followed by the 3' UTR and contiguous NCR; a second functional unit, elements of said second unit comprise a response element corresponding to the receptor; a thymidine kinase promoter; the specific nucleic acid sequence of interest; a myogenic specific 3' UTR and a contiguous myogenic specific NCR; wherein the elements of the second unit are linked together sequentially starting from the 5' end with the response element followed by promoter followed by the specific sequence, followed by the 3' UTR and NCR; wherein the first unit expresses the receptor, said receptor forming an interaction between the response element, the receptor and an agent which binds to the receptor, said interaction up regulating the expression of the sequence of interest. 24. The MVS of claim 23 wherein the first and second functional units are on the same vector. 25. The MVS of claim 23, wherein the first and second functional units are on separate vectors. 26. The MVS of claim 23, wherein the receptor is selected from the family of receptors consisting of vitamin, steroid, thyroid, orphan, hormone, retinoic acid and thyroxine. 27. The MVS of claim 23 wherein the receptor is the Vitamin D receptor, the response element is a Vitamin D response element and agent is Vitamin D. 28. The MVS of claim 1, 3 or 23, further comprising a coating, said coating includes: a DNA initiation complex, said DNA initiation complex comprises a serum response factor (SRF), a transcription initiation factor (TIF) and a transregulatory factor (TRF), wherein the SRF is bound to a serum response element within the promoter, the TIF and TRF interact with the SRF and a TATA box within the promoter to form a stable complex; and histones, said histones bound nonspecifically to the remaining DNA in said MVS. 29. The MVS of claim 11, further comprising a coating, said coating including: a DNA initiation complex, said DNA initiation complex comprising a serum response factor (SRF), transcription initiation factor (TIF) and a transregulatory factor (TRF), wherein the SRF is attached to a serum response element within the promoter, the TIF and TRF interact with the SRF and a TATA box within the promoter to form a stable complex; and histones, said histones bound nonspecifically to the remaining DNA in said MVS. 30. The MVS of claim 12, further comprising a coating, said coating includes: a DNA initiation complex, said DNA initiation complex comprises a serum response factor (SRF), a transcription initiation factor (TIF) and a transregulator factor (TRF), wherein the SRF is attached to a serum response element within the promoter, the TIF and TRF interact with the SRF and a TATA box within the promoter to form a stable complex; and histones, said histones bound nonspecifically to the remaining DNA in said MVS. 31. The MVS of claim 8, wherein the 5' oligonucleotide further includes a leader sequence. 32. The MVS of claim 1 or 3, wherein the nucleic acid sequence to be expressed is heterologous relative to the 3' UTR and NCR in the MVS.

Details for Patent 5,298,422

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26